Ovarian Cancer Diagnosis and Management

Symptoms and Risk Factors

• The European Society of Gynaecological Oncology recommends that most women are diagnosed based on symptoms, with the majority presenting at an advanced stage due to the lack of reliable screening methods 1
• Common symptoms include abdominal/pelvic pain, which is a significant indicator of ovarian cancer, especially in postmenopausal women 2, 1, 3
• The American College of Obstetricians and Gynecologists notes that other symptoms such as constipation or diarrhea, urinary frequency, vaginal bleeding, abdominal distension, and fatigue are also associated with ovarian cancer 2
• In advanced disease, symptoms like bloating, nausea, anorexia, dyspepsia, and early satiety due to ascites and abdominal masses are common, according to the National Comprehensive Cancer Network 2
• Respiratory symptoms from pleural effusions in cases with thoracic extension are also possible, as stated by the European Respiratory Society 2

Diagnostic Workup Algorithm

• The standard workup for patients with suspected epithelial ovarian cancer, as recommended by the American College of Radiology, must include a detailed history, clinical examination, serum CA-125, transvaginal/transabdominal ultrasound, CT of thorax/abdomen/pelvis, and pathological examination of tumor samples 2, 4, 1
• A detailed history focusing on risk factors, such as family history of ovarian/breast cancer, BRCA mutations, and Lynch syndrome, is crucial, according to the American Society of Clinical Oncology 1, 3
• Clinical examination to detect pelvic masses or ascites is also essential, as stated by the European Society of Gynaecological Oncology 2
• Serum CA-125 is elevated in ~85% of advanced disease but only ~50% of early-stage cases, notes the National Cancer Institute 2, 4
• For suspected mucinous carcinoma, Serum CEA and CA 19-9 are recommended, especially if CA-125/CEA ratio is ≤25/1, according to the American College of Pathologists 2, 4
• Transabdominal and transvaginal ultrasound by an expert examiner is necessary, as recommended by the American Institute of Ultrasound in Medicine 2, 4
• CT scan of thorax, abdomen, and pelvis for complete clinical staging and surgical planning is also required, states the American College of Radiology 2, 4

Special Considerations

• For mucinous carcinoma, additional gastrointestinal tract evaluation and CEA level to distinguish between primary ovarian tumors and metastases are necessary, according to the National Comprehensive Cancer Network 5
• For germ cell tumors, measure AFP, β-hCG, and LDH, recommends the European Society for Medical Oncology 6
• Consider genetic testing for patients with family history of ovarian/breast cancer (BRCA1/2 mutations) or Lynch syndrome (mismatch repair genes), advises the American Society of Clinical Oncology 1, 3

Common Pitfalls to Avoid

• Misinterpreting CA-125 levels, as CA-125 is not specific to ovarian cancer and may be elevated in non-gynecological malignancies and benign conditions, warns the American College of Obstetricians and Gynecologists 2
• Inadequate imaging, relying solely on ultrasound without CT for complete staging, is a common pitfall, notes the American College of Radiology 2
• Insufficient tissue sampling, obtaining inadequate tumor samples for pathological examination, especially if neoadjuvant chemotherapy is planned, is also a concern, states the College of American Pathologists 2
• Missing mucinous carcinoma origin, failing to distinguish between primary mucinous ovarian tumors and gastrointestinal metastases, is another potential error, according to the National Comprehensive Cancer Network 5

Diagnostic Workup and Imaging for Complex Ovarian Cysts

Initial Clinical Assessment

• Perform a thorough abdominal and pelvic examination to identify pelvic masses, nodularity, fixation, or ascites, which may indicate malignancy. (National Comprehensive Cancer Network) 7

Imaging Protocol

Primary Imaging

• Transvaginal ultrasound with color or power Doppler is the first‑line imaging modality for evaluating a complex ovarian cyst. (NCCN) 7
• Ultrasound features that raise suspicion for malignancy include solid components, papillary projections, thick septations greater than 2–3 mm, presence of ascites, bilateral masses, or irregular cyst borders. (NCCN) 7

Advanced Imaging

• Contrast‑enhanced CT of the chest, abdomen, and pelvis is required for complete staging and surgical planning when ovarian malignancy is suspected. (NCCN) 7
• Magnetic resonance imaging (MRI) is recommended when ultrasound findings are indeterminate or insufficient to assess malignant potential. (NCCN) 7
• Fluorodeoxyglucose PET/CT may be employed for lesions that remain indeterminate after standard ultrasound and CT evaluation. (NCCN) 7

Laboratory Testing

• In patients younger than 35 years, serum α‑fetoprotein (AFP) and β‑human chorionic gonadotropin (β‑hCG) should be measured to exclude germ‑cell tumors. (NCCN) 7

Procedural Pitfalls

• Fine‑needle aspiration or percutaneous biopsy of a presumed early‑stage ovarian cyst should be avoided because it can cause cyst rupture and peritoneal spillage of malignant cells, potentially upstaging the disease. (NCCN) 7

Diagnostic Workup for Suspected Ovarian Cancer

Clinical Assessment

• A comprehensive evaluation should include transvaginal ultrasound, serum CA‑125 measurement, and contrast‑enhanced CT of the chest, abdomen, and pelvis, followed by pathological examination of tumor tissue obtained by surgery or biopsy. 8
• Pelvic examination can identify masses, ascites, or fixed nodules, but its low sensitivity means a negative exam should not delay further imaging. 8
• Palpable inguinal, axillary, or supraclavicular lymphadenopathy may indicate metastatic disease and warrants further work‑up. 9

Laboratory Testing

• CA‑125 is elevated in ~85 % of advanced epithelial ovarian cancer and in ~50 % of early‑stage (FIGO I) disease; however, it lacks specificity because it can rise in many benign conditions. [9][8]
• For suspected mucinous ovarian carcinoma, obtain CEA and CA 19‑9 in addition to CA‑125; a CA‑125/CEA ratio ≤ 25 : 1 suggests a gastrointestinal primary rather than a primary ovarian tumor. Endoscopic evaluation (colonoscopy/gastroscopy) is advised when CEA or CA 19‑9 are elevated. 8
• In patients ≤ 35 years or when germ‑cell tumors are suspected, order α‑fetoprotein (AFP), β‑human chorionic gonadotropin (β‑hCG), and lactate dehydrogenase (LDH) as tumor markers. [10][11]12
• For suspected sex‑cord stromal tumors, inhibin is a useful serum marker. 12
• Baseline laboratory studies should include a complete blood count and assessment of hepatic and renal function. [11][12]

Imaging Studies

• Transvaginal and transabdominal ultrasound performed by an expert examiner is the first‑line imaging modality; ultrasound‑based models (IOTA Simple Rules or ADNEX) outperform CA‑125 alone for distinguishing benign from malignant masses. 8
• Sonographic features that raise suspicion for malignancy (as defined by NCCN) include: lesion size > 6 cm, solid components or papillary projections, thick (>2–3 mm) or irregular septations, presence of ascites, bilateral ovarian masses, and increased Doppler vascular flow. 10
• Contrast‑enhanced CT of the chest, abdomen, and pelvis is required for complete clinical staging and surgical planning. 8
• MRI is recommended when ultrasound findings are indeterminate or when detailed soft‑tissue characterization is needed. [10][8]
• FDG‑PET/CT may be employed for lesions that remain indeterminate after standard CT/MRI evaluation. 10
• If a pleural effusion is present and safely accessible, obtain pleural fluid for cytology. 8

Pathological Diagnosis

• Definitive diagnosis mandates histopathologic examination of adequate tumor tissue. Surgical specimens obtained during staging laparotomy or laparoscopy are preferred. [12][8]
• Fine‑needle aspiration should be avoided in presumed early‑stage disease to prevent capsular rupture and peritoneal spillage, which can upstage the tumor. 10
• Image‑guided or laparoscopic core biopsy is appropriate for patients with bulky disease who are not immediate surgical candidates. 10
• Pathology must be performed by an expert gynecologic pathologist, using WHO 2020 classification criteria, and sufficient tissue should be retained for molecular/genetic testing, especially before neoadjuvant chemotherapy. [12][8]

Special Considerations

• In pre‑menarchal patients with suspected gonadoblastoma, obtain a pre‑operative karyotype because these tumors often arise in dysgenetic gonads. 12
• For granulosa‑cell tumors, perform endometrial sampling (curettage) to exclude synchronous endometrial carcinoma. 12
• Offer BRCA1/2 genetic testing to patients with a family history of breast or ovarian cancer, as recommended by NCCN. 10

Critical Pitfalls to Avoid

• Do not rely on CA‑125 alone for diagnosis or staging; its sensitivity is insufficient for early disease and its specificity is limited. 8
• Do not perform fine‑needle aspiration on presumed early‑stage ovarian masses due to the risk of tumor rupture and peritoneal contamination. 10
• Do not use ultrasound alone for staging; a contrast‑enhanced CT of the chest, abdomen, and pelvis is mandatory for comprehensive staging. 8
• In mucinous ovarian tumors, failure to measure CEA and CA 19‑9 (or to assess the CA‑125/CEA ratio) may miss a gastrointestinal primary. 8
• Ensure adequate tumor tissue is obtained before initiating neoadjuvant chemotherapy to allow for necessary molecular testing. 8

Strength of evidence: Not explicitly graded in the source articles; recommendations are based on consensus and expert opinion from the cited societies.